Altimmune Inc (ALT) 재무 분석
*모든 숫자는 백만 단위입니다.
| 기간 종료일 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| 기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
8.19%26.23 | 24.24 | 28.92 | 20.86 | 22.93 | |
| Research and Development | 15.21%18.66 | 16.19 | 18.41 | 14.96 | 17.24 |
| Operating Income/Loss | 8.19%-26.23 | -24.24 | -28.89 | -20.86 | -22.92 |
| Nonoperating Income/Loss | 102.50%3.40 | 1.68 | 1.54 | 1.85 | 0.78 |
| Income/Loss From Continuing Operations Before Tax | 1.16%-22.83 | -22.56 | -27.36 | -19.01 | -22.15 |
1.16%-22.83 | -22.56 | -27.36 | -19.01 | -22.15 | |
| Attributable To Parent | 1.16%-22.83 | -22.56 | -27.36 | -19.01 | -22.15 |
| Basic Average Shares | 49.00%185.44 | 124.46 | 5.91 | 89.42 | 81.48 |
| Diluted Average Shares | 49.00%185.44 | 124.46 | 5.91 | 89.42 | 81.48 |
| Basic Earnings Per Share | 33.33%-0.12 | -0.18 | -0.26 | -0.21 | -0.27 |
| Diluted Earnings Per Share | 33.33%-0.12 | -0.18 | -0.26 | -0.21 | -0.27 |